Convelo Therapeutics is committed to developing medicines to regenerate myelin around nerve cells and restoring function to patients with neurological disorders. The company was founded in 2016 by Case Western Reserve University School of Medicine professors Paul Tesar, PhD and Drew Adams, PhD to translate discoveries from their laboratories into medicines for critically ill patients.
Founded in 2017 by biomedical industry veterans William Fuller and Dr. Emile Daoud, Cleveland-based S4 Medical is a medical device company focused on innovative solutions for cardiac procedures to treat atrial fibrillation. The company’s initial product is a simple, yet comprehensive solution for reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation. S4 Medical
BioMendics has developed wound-healing formulations that blend liquid crystals with natural products to produce a cutting-edge accelerated healing product for wound care. Their lead product, TegSure™, targets all phases of the wound healing process and can be used alone or in conjunction with other wound care technologies. Biomendics is a JumpStart portfolio company. The investment came
AnalizaDx, LLC is a cancer diagnostics company that has developed and is presently commercializing a proprietary platform technology to improve cancer detection, diagnosis, progression and prognosis. A spin-off company from Analiza, Inc., AnalizaDx’s cancer detection technology differs from conventional biomarker technologies that measure the amount of a disease-related protein, as it identifies biomarkers based on
CardioInsight Technologies is commercializing a breakthrough technology designed to improve the diagnosis and treatment of electrical disorders of the heart. The company’s non-invasive electrocardiographic mapping platform, the ECVue system, gathers electrical information about the heart from a proprietary, multi-sensor electrode “vest” placed on a patient’s body and combines it with images from a CT scan
The mission of Checkpoint Surgical is to provide physicians with medical devices to locate, evaluate and protect nerves and muscles in surgical procedures for better patient outcomes. The Company’s flagship product, the CHECKPOINT® Stimulator/Locator is a single-use, hand-held stimulator with a broad range of stimulation parameters that are fully controllable by the surgeon. The CHECKPOINT®
CoverMyMeds LLC helps physicians and pharmacists complete Prior Authorization and other insurance coverage determination forms for any drug and almost all drug plans. The company has developed online and phone-based tools that speed up and automate the submission of Prior Authorization requests to health insurance plans. CoverMyMeds does not charge pharmacies or doctors for using
Cryothermic Systems, Inc. is a medical device company committed to improving patient outcomes. The company has developed a novel approach to selectively cooling the brain to induce mild therapeutic hypothermia and protect patients from ischemic and re-perfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury. Cryothermic Systems, Inc. is a JumpStart
Endotronix, Inc. is a medical device company dedicated to wireless health monitoring for congestive heart failure (CHF) patients. The company is developing miniaturized, wireless pressure sensors that are implanted as part of interventional cardiovascular procedures and interface to an external measurement instrument. Endotronix’s “Anytime, Anywhere” wireless sensing platform technology will provide long term patient data
Battling cancer, one genome at a time. An emerging player in the field of genomics, GenomOncology’s proprietary software and analytical tools can rapidly and interactively analyze and interpret sequenced genomic data. This approach enables GenomOncology to capture critical findings for the cancer researcher or clinical oncologist and produce a robust analysis report in less than
Juventas Therapeutics is a biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. The company’s lead product, Stromal-cell Derived Factor 1 (SDF-1), has been shown to protect and repair tissue following organ-damage in a broad range of pre-clinical disease models. Juventas’ first clinical target will be treatment of patients with advanced heart
Milo Biotechnology is a Cleveland-based company dedicated to improving the lives of patients with neuromuscular diseases. Milo’s early clinical stage follistatin program, exclusively licensed from Nationwide Children’s Hospital, is designed to increase muscle size and strength. Milo Biotechnology is a JumpStart portfolio company. The investment came from the JumpStart Evergreen Fund.